ICLR Stock Analysis: ICON | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 13.257m USD | 12M Return: 10.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 144M
EPS Trend: -14.3%
Qual. Beats: 0
Rev. Trend: 48.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ICON Public Limited Company (ICLR) is a Dublin-headquartered clinical research organization (CRO) that provides outsourced drug and medical device development services to pharmaceutical, biotechnology, and medical device companies, as well as government and public health organizations. Founded in 1989 and listed on NASDAQ since 1998, ICON operates across Ireland, the rest of Europe, the United States, and other international markets, supporting clients from compound selection through Phase I–IV clinical studies, as well as peri- and post-approval work, data solutions, and site and patient access services. Its offerings span clinical trial management, consulting, contract staffing, commercial strategy and post-market commercialization, and a broad laboratory services portfolio that includes bioanalytical, biomarker, vaccine, good manufacturing practice (GMP), and central laboratory capabilities, delivered through both full-service and functional service partnership models. The company also provides specialized solutions such as adaptive trials, cardiac safety, decentralized and hybrid clinical trials, medical imaging, real-world intelligence, and language services, and maintains a strategic alliance with Advarra to build a connected, research-ready clinical trial site network.
CROs like ICON act as external development partners for drug and device sponsors, managing the operational, regulatory, and data aspects of clinical programs so clients can focus resources on discovery and commercialization. The industrys growth has been supported in recent years by rising R&D outsourcing rates among large pharma, increased clinical trial complexity, and the expansion of decentralized and hybrid trial designs.
- Biotech funding weakness pressures clinical trial bookings
- Lab services margins expand on biomarker and vaccine demand
- Medpace competition intensifies in small-mid biotech segment
| Net Income: 179.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -1.48 > 1.0 |
| NWC/Revenue: 5.28% < 20% (prev 8.87%; Δ -3.59% < -1%) |
| CFO/TA 0.06 > 3% & CFO 971.9m > Net Income 179.9m |
| Net Debt (2.85b) to EBITDA (1.25b): 2.28 < 3 |
| Current Ratio: 1.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (77.3m) vs 12m ago -6.05% < -2% |
| Gross Margin: 24.10% > 18% (prev 29.00%; Δ -4.90% > 0.5%) |
| Asset Turnover: 50.14% > 50% (prev 48.99%; Δ 1.15% > 0%) |
| Interest Coverage Ratio: 4.63 > 6 (EBIT TTM 872.2m / Interest Expense TTM 188.5m) |
| A: 0.03 (Total Current Assets 3.61b - Total Current Liabilities 3.17b) / Total Assets 16.3b |
| B: 0.14 (Retained Earnings 2.23b / Total Assets 16.3b) |
| C: 0.05 (EBIT TTM 872.2m / Avg Total Assets 16.5b) |
| D: 1.33 (Book Value of Equity 9.30b / Total Liabilities 7.02b) |
| Altman-Z'' = 2.37 = BBB |
| DSRI: 0.98 (Receivables 2.70b/2.74b, Revenue 8.28b/8.19b) |
| GMI: 1.20 (GM 29.00% / 24.10%) |
| AQI: 0.98 (AQ_t 0.75 / AQ_t-1 0.76) |
| SGI: 1.01 (Revenue 8.28b / 8.19b) |
| TATA: -0.05 (NI 179.9m - CFO 971.9m) / TA 16.3b) |
| Beneish M = -2.87 (Cap -4..+1) = A |
As of July 12, 2026, the stock is trading at USD 167.72 with a total of 290,963 shares traded. Over the past week, the price has changed by -3.09%, over one month by +16.00%, over three months by +57.03% and over the past year by +10.29%.
Current recommended Stop Loss: 151.20 (which is 9.8% or 2.2 ATR below the current price).
ICON has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy ICLR.
- StrongBuy: 11
- Buy: 0
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 178.3 | 6.3% |
P/E Trailing = 76.2379
P/E Forward = 16.5563
P/S = 1.603
P/B = 1.4254
P/EG = 0.5576
Revenue TTM = 8.28b USD
EBIT TTM = 872.2m USD
EBITDA TTM = 1.25b USD
Long Term Debt = 2.87b USD (from longTermDebt, last quarter)
Short Term Debt = 529.8m USD (from shortTermDebt, last quarter)
Debt = 3.62b USD (from shortLongTermDebtTotal, last quarter) + Leases 111.3m
Net Debt = 2.85b USD (calculated: Debt 3.62b - CCE 765.2m)
Enterprise Value = 16.1b USD (13.3b + Debt 3.62b - CCE 765.2m)
Interest Coverage Ratio = 4.63 (Ebit TTM 872.2m / Interest Expense TTM 188.5m)
EV/FCF = 20.38x (Enterprise Value 16.1b / FCF TTM 790.5m)
FCF Yield = 4.91% (FCF TTM 790.5m / Enterprise Value 16.1b)
FCF Margin = 9.54% (FCF TTM 790.5m / Revenue TTM 8.28b)
Net Margin = 2.17% (Net Income TTM 179.9m / Revenue TTM 8.28b)
Gross Margin = 24.10% ((Revenue TTM 8.28b - Cost of Revenue TTM 6.29b) / Revenue TTM)
Gross Margin QoQ = 23.50% (prev 22.87%)
Tobins Q-Ratio = 0.99 (Enterprise Value 16.1b / Total Assets 16.3b)
Interest Expense / Debt = 5.21% (Interest Expense 188.5m / Debt 3.62b)
Taxrate = 12.76% (26.3m / 206.3m)
NOPAT = 760.9m (EBIT 872.2m * (1 - 12.76%))
Current Ratio = 1.14 (Total Current Assets 3.61b / Total Current Liabilities 3.17b)
Debt / Equity = 0.39 (Debt 3.62b / totalStockholderEquity, last quarter 9.30b)
Debt / EBITDA = 2.28 (Net Debt 2.85b / EBITDA 1.25b)
Debt / FCF = 3.61 (Net Debt 2.85b / FCF TTM 790.5m)
Total Stockholder Equity = 9.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.09% (Net Income 179.9m / Total Assets 16.3b)
RoE = 1.93% (Net Income TTM 179.9m / Total Stockholder Equity 9.35b)
RoCE = 7.14% (EBIT 872.2m / Capital Employed (Equity 9.35b + L.T.Debt 2.87b))
RoIC = 5.74% (NOPAT 760.9m / Invested Capital 13.3b)
WACC = 8.40% (E(13.3b)/V(16.9b) * Re(9.45%) + D(3.62b)/V(16.9b) * Rd(5.21%) * (1-Tc(0.13)))
Discount Rate = 9.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -67.42 | Cagr: -3.19%
[DCF] Terminal Value 72.92% ; FCFF base≈897.5m ; Y1≈787.1m ; Y5≈635.9m
[DCF] Fair Price = 94.95 (EV 10.1b - Net Debt 2.85b = Equity 7.27b / Shares 76.6m; r=8.40% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -14.34 | EPS CAGR: -1.07% | SUE: 0.18 | # QB: 0
Revenue Correlation: 48.62 | Revenue CAGR: 0.87% | SUE: 0.38 | # QB: 0
EPS current Quarter (2026-06-30): EPS=2.54 | Chg30d=-0.83% | Revisions=-50% | Analysts=14
EPS next Quarter (2026-09-30): EPS=2.71 | Chg30d=+0.31% | Revisions=+0% | Analysts=14
EPS current Year (2026-12-31): EPS=10.63 | Chg30d=+0.30% | Revisions=-21% | GrowthEPS=-15.1% | GrowthRev=-2.4%
EPS next Year (2027-12-31): EPS=11.86 | Chg30d=+0.74% | Revisions=-31% | GrowthEPS=+11.5% | GrowthRev=+3.1%
[Analyst] Revisions Ratio: -30% (up=17, down=33)